Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. GERN
GERN logo

GERN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Geron Corp (GERN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.490
1 Day change
-4.49%
52 Week Range
2.010
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Geron Corp (GERN) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows some positive trends, such as hedge fund buying and slight improvements in financials, the lack of significant positive catalysts, neutral technical indicators, and a recent price target downgrade suggest that holding off on a purchase is prudent. The stock does not currently present a compelling entry point.

Technical Analysis

The technical indicators are mixed. The MACD is above zero but contracting, indicating weakening bullish momentum. The RSI is neutral at 50.9, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). However, the stock is trading below its pivot point of 1.716, with key support at 1.62 and resistance at 1.811.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
7
Buy
5

Positive Catalysts

  • Hedge funds are significantly increasing their positions, with a 226.92% increase in buying over the last quarter. The company's revenue and net income have shown slight YoY improvements in Q4 2025.

Neutral/Negative Catalysts

  • No recent news or significant insider activity. Analysts have lowered the price target from $4 to $3, reflecting reduced optimism. Gross margin has slightly declined YoY. The stock has no recent AI Stock Picker or SwingMax signals.

Financial Performance

In Q4 2025, revenue increased by 1.01% YoY to $48,015,000, and net income improved by 13.85% YoY to -$28,862,000. EPS remained unchanged at -0.04, while gross margin dropped slightly to 97.28%, down 1.09% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

TD Cowen analyst Tara Bancroft maintains a Buy rating but has lowered the price target from $4 to $3, indicating tempered expectations for the stock's performance.

Wall Street analysts forecast GERN stock price to rise
4 Analyst Rating
Wall Street analysts forecast GERN stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.560
sliders
Low
4
Averages
4
High
4
Current: 1.560
sliders
Low
4
Averages
4
High
4
TD Cowen
Tara Bancroft
Buy
downgrade
$4 -> $3
AI Analysis
2026-01-29
Reason
TD Cowen
Tara Bancroft
Price Target
$4 -> $3
AI Analysis
2026-01-29
downgrade
Buy
Reason
TD Cowen analyst Tara Bancroft lowered the firm's price target on Geron to $3 from $4 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 results.
Goldman Sachs
initiated
$1
2025-07-10
Reason
Goldman Sachs
Price Target
$1
2025-07-10
initiated
Reason
Goldman Sachs resumed coverage of Geron with a Sell rating and $1 price target, which suggests 31% downside. The initial launch of the company's lead product and first commercial drug, Rytelo, has disappointed, and the near-term trajectory for the launch will be modest, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GERN
Unlock Now

People Also Watch